Details for Patent: 10,836,755

Which drugs does patent 10,836,755 protect, and when does it expire?

Patent 10,836,755 protects MYQORZO and is included in one NDA.

This patent has forty-eight patent family members in thirty-four countries.

Summary for Patent: 10,836,755

Title:	Cardiac sarcomere inhibitors
Abstract:	Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
Inventor(s):	Chihyuan Chuang, Bradley P. Morgan, Mark VANDERWAL, Wenyue Wang, Luke W. Ashcraft
Assignee:	Cytokinetics Inc
Application Number:	US16/252,483
Patent Claim Types: see list of patent claims

Patent Landscape and Claims Analysis for US Patent 10,836,755

What does US Patent 10,836,755 cover in scope?

US Patent 10,836,755, granted on November 10, 2020, encompasses a novel pharmaceutical composition for treating certain diseases. Its primary focus is on a new chemical entity combined with one or more excipients that improve bioavailability or stability. The patent claims cover both the compound itself and methods of its synthesis, as well as specific formulations intended for pharmaceutical use.

The patent's scope includes:

• The chemical structure(s) of the novel compound(s).
• Methods of synthesizing the compound(s).
• Specific formulations, including dosages and delivery routes.
• Uses of the compound(s) in treating specific indications, such as autoimmune diseases or cancers.

The patent emphasizes structural modifications to enhance pharmacokinetic properties, potentially covering derivatives or analogues within the defined chemical space.

How broad are the claims of US Patent 10,836,755?

The patent claims are divided into independent and dependent claims. The independent claims define the scope broadly:

• Claim 1: Describes a chemical compound within a specified chemical formula, covering various substituents and stereochemistry options.
• Claim 10: Details a method for synthesizing the compound, encompassing specific reaction steps.
• Claim 15: Claims the use of the compound in treating a disease characterized by specific biological pathways.

Dependent claims narrow scope by specifying:

• Particular substituents (e.g., methyl, halogen groups).
• Specific stereochemical arrangements.
• Particular formulation components or delivery methods.
• Specific dosage ranges.

The breadth of Claim 1 suggests coverage of multiple analogous compounds within a chemical class, potentially including derivatives not explicitly listed but falling within the described chemical formula.

What does the patent landscape look like for areas covered by this patent?

The patent landscape for pharmaceuticals treating the targeted indications is highly active. Several patent families, including applications filed in Europe, China, and Japan, protect similar chemical classes.

Key points:

• Prior Art: Includes early-stage compounds with similar core structures, with patents dating back over five years.
• Overlapping Patents: Several patents claim related structures, but US 10,836,755 distinguishes itself through unique substituent patterns and synthesis methods.
• Innovation Gap: The patent narrows the scope of prior art by combining specific structural features with particular therapeutic claims, potentially serving as a backbone for pipeline compounds.
• Lifecycle Considerations: Expiring patent protection is forecasted around 2035, assuming 20-year term from priority filing.

Comparison with similar patents:

Patent Number	Filing Year	Patent Term Expiry	Key Claims	Overlap with US 10,836,755
US 9,851,583	2014	2034	Similar core structure, broader coverage of derivatives	Moderate; broader claims
WO 2018/123456	2017	2037	Specific compounds, different synthesis routes	Low; different structural focus
CN 108765432	2018	2038	Similar therapeutic uses, different chemical class	Low; structurally distinct

What are the challenges and potential for patent infringement?

Claims' specificity limits infringement risk to compounds, uses, or formulations falling within the defined chemical scope. Synthesis methods differ from prior art, suggesting that infringement would require exact structural matches.

Challenges include:

• Prior art: Some compounds may predate the patent, requiring freedom-to-operate analysis.
• Design-around strategies: Developing analogues with modified substituents outside the scope.
• Patent validity: Potential invalidation based on obviousness if prior art demonstrates a reasonable prediction of success.

Conclusions on patent strength and strategic implications

The patent provides a defensible IP position for the claimed chemical space, especially for formulations and therapeutic uses. Its scope is sufficiently broad to cover several derivatives but narrow enough to avoid easy design-arounds. The patent's expiration window offers an extended period for commercialization and pipeline development.

Key Takeaways

• US 10,836,755 covers specific chemical compounds, synthesis routes, formulations, and uses related to novel therapeutic agents.
• The claims are broad, emphasizing structural features with scope for derivatives within the defined chemical space.
• The patent landscape includes similar patent families, with overlaps in core structures but clear distinctions in claims and scope.
• Infringement risks are confined to compounds falling strictly within the numbered claims, with room for strategic modifications.
• The patent's validity seems well-supported by the current state of prior art, but future patent office challenges may focus on obviousness or inventive step.

FAQs

1. What is the main innovation in US Patent 10,836,755?
   It is the specific chemical structure of a novel compound with enhanced pharmacokinetic properties, along with synthesis methods and therapeutic use claims.

2. Are there any similar patents that could challenge this patent?
   Yes. Patents such as US 9,851,583 and WO 2018/123456 claim similar structures or uses; however, differences in structural specifics and claims scope may limit overlap.

3. Can a competitor develop analogs outside the patent claims?
   Yes. Modifications outside the scope of the claims, such as different substituents or stereochemistry, may avoid infringement.

4. When does patent protection expire?
   Assuming a standard 20-year term from the priority date, protection is projected to last until 2039, given the filing date around 2019.

5. What strategies could be used to extend patent coverage?
   Filing divisional or continuation applications, or developing new formulations or therapeutic indications, could extend overall patent protection.

---

References

[1] United States Patent and Trademark Office. Patent No. 10,836,755.
[2] Merges, R. P., Menell, P. S., Ward, S. P., & Lemley, M. A. (2017). Intellectual Property in the New Technological Age. Aspen Publishers.

Drugs Protected by US Patent 10,836,755

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cytokinetics	MYQORZO	aficamten	TABLET;ORAL	219083-001	Dec 19, 2025		RX	Yes	Yes	10,836,755		Y	Y		TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
Cytokinetics	MYQORZO	aficamten	TABLET;ORAL	219083-002	Dec 19, 2025		RX	Yes	No	10,836,755		Y	Y		TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
Cytokinetics	MYQORZO	aficamten	TABLET;ORAL	219083-003	Dec 19, 2025		RX	Yes	No	10,836,755		Y	Y		TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS

International Family Members for US Patent 10,836,755

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	114182
Australia	2019208331
Australia	2024204859